• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

    5/10/22 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care
    Get the next $INO alert in real time by email

    Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech

    PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO) of INOVIO, effective immediately. Dr. Shea succeeds Dr. J. Joseph Kim in these roles.  Dr. Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr. Shea as a director following INOVIO's annual meeting of the stockholders on May 16, 2022.

    Mr. Simon X. Benito, Chairman of the Board of INOVIO, said, "On behalf of the entire Board, I am pleased to announce Dr. Shea's appointment as President and CEO of INOVIO. Dr. Shea brings more than 25 years of experience in the life sciences and biotech industries. Since joining as Chief Operating Officer in March 2019, Dr. Shea has shown exceptional leadership and technical expertise overseeing INOVIO's manufacturing, commercial, business development, project and alliance management operations as well as serving as a key member of the executive team. We look forward to Dr. Shea taking the helm during a particularly challenging period in INOVIO's history. Her tenured leadership, deep knowledge of our business, and broad expertise makes her an excellent choice for the role."

    Mr. Benito added, "On behalf of the Board, I would like to thank Dr. Kim for his commitment to INOVIO and his founding vision of a world free from disease through DNA medicines. As a co-founder of the Company, Joseph has been a true entrepreneur and pioneer in the field of vaccines and immunotherapies since its inception.  I am pleased that he has agreed to act in an advisory capacity to Dr. Shea during the transition."

    Dr. Shea said, "I am honored to take on the role of CEO and grateful for the support of the Board in entrusting me to lead INOVIO for its next chapter. While we have many challenges to face, I believe strongly in the potential of our DNA medicines technology and continue to be inspired by INOVIO's talented and dedicated team. I look forward to reshaping the future of INOVIO and advancing our efforts across multiple therapeutic areas with the potential to improve the lives of patients globally."

    Prior to joining INOVIO in March 2019, Dr. Shea served as the Chief Operating Officer and later the Chief Executive Officer of Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB). During her tenure she oversaw two major clinical trial breakthroughs in the development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium. A molecular biologist and cell cycle geneticist, Dr. Shea received a BSc Hons in Applied Biology from the University of Bath and holds a Ph.D. from the National Institute for Medical Research in the United Kingdom. She has been named as an inventor on more than 20 patents, has authored numerous publications, served on multiple advisory boards and currently serves on the board of Trustees for the Sabin Vaccine Institute.  

    About INOVIO

    INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases, cancer, and diseases associated with HPV. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers.

    Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com.

    CONTACTS:

    Investors: Ben Matone, 484-362-0076, [email protected]

    Media: Jeff Richardson, 267-440-4211, [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/inovio-announces-the-appointment-of-jacqueline-shea-phd-as-chief-executive-officer-301544321.html

    SOURCE INOVIO Pharmaceuticals, Inc.

    Get the next $INO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INO

    DatePrice TargetRatingAnalyst
    5/14/2024$20.00Overweight
    Stephens
    1/25/2024$4.00Perform → Outperform
    Oppenheimer
    11/9/2022Buy → Hold
    Maxim Group
    11/1/2022$2.00Neutral → Underperform
    BofA Securities
    7/19/2022$5.00 → $4.00Sector Perform
    RBC Capital Mkts
    5/11/2022Outperform → Perform
    Oppenheimer
    3/2/2022$6.00 → $5.00Sector Perform
    RBC Capital
    1/21/2022$8.00 → $10.00Underperform → Neutral
    B of A Securities
    More analyst ratings

    $INO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INOVIO to Present at Upcoming Scientific and Investor Conferences

      PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.

      4/30/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Present at Upcoming Scientific Conferences

      PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.

      4/9/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

      SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/26/24 4:01:17 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      1/22/24 10:20:28 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      7/10/23 2:07:33 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Inovio Pharma with a new price target

      Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

      5/14/24 8:01:14 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

      1/25/24 7:27:17 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma downgraded by Maxim Group

      Maxim Group downgraded Inovio Pharma from Buy to Hold

      11/9/22 9:19:58 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Humeau Laurent converted options into 8,865 shares and covered exercise/tax liability with 3,643 shares, increasing direct ownership by 21% to 29,559 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:06:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Sumner Michael John converted options into 5,010 shares, increasing direct ownership by 61% to 13,229 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:05:49 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Shea Jacqueline Elizabeth converted options into 24,484 shares and covered exercise/tax liability with 11,581 shares, increasing direct ownership by 38% to 46,550 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:05:39 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Leadership Updates

    Live Leadership Updates

    See more
    • INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

      PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

      1/9/25 8:04:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

      Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

      7/2/24 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

      PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic

      6/27/22 8:00:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Financials

    Live finance-specific insights

    See more
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

      3/18/25 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

      PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online

      3/12/25 12:55:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Inovio Pharmaceuticals Inc.

      SCHEDULE 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/30/25 11:24:07 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Inovio Pharmaceuticals Inc.

      SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/17/25 9:35:29 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Inovio Pharmaceuticals Inc.

      DEF 14A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

      4/7/25 4:08:23 PM ET
      $INO
      Medical/Dental Instruments
      Health Care